The wall between specialty palliative care and the rest of medicine is more permeable than assumed.
For millions of Americans living with serious illness, the promise of palliative care — relief from pain, dignity in suffering — has remained structurally out of reach, not for lack of compassion but for lack of trained hands. A landmark trial conducted across nineteen U.S. medical centers has now demonstrated that liver specialists, equipped with structured training and a standardized approach, can deliver that care as effectively as dedicated palliative experts. The PAL LIVER trial, enrolling 935 patients with advanced liver disease, quietly challenges a long-held assumption: that the boundary between specialty care and the rest of medicine is fixed, when in fact it may simply be untended.
- Over 13.7 million Americans with serious illnesses currently cannot access adequate palliative care, a shortage that worsens as the population ages and chronic disease rises.
- The PAL LIVER trial — one of the largest of its kind — put a direct question to the system: can a trained liver specialist do what a palliative care expert does, and the answer was an unambiguous yes.
- Patients reported higher satisfaction when palliative care came from their own hepatologist, suggesting that continuity of relationship carries therapeutic weight that credentials alone cannot replicate.
- The checklist-based training model used in the trial points toward a scalable solution — embedding palliative capacity inside existing clinical teams rather than waiting decades to train more specialists.
- Researchers are already moving to extend the model to heart, kidney, and lung disease patients, and are exploring AI tools to accelerate adoption across health systems.
For patients whose livers are failing, the medical journey is often marked not only by the disease itself but by the absence of anyone focused on easing the suffering it brings. Palliative care — concerned with pain, symptoms, and quality of life rather than cure — remains inaccessible to many of the country's sickest people. A major new clinical trial suggests that does not have to remain true.
The PAL LIVER trial enrolled 935 patients with advanced liver disease across 19 U.S. medical centers, along with 559 of their caregivers. Its central question was whether a liver specialist, trained with a standardized checklist, could deliver palliative care as effectively as a dedicated expert. Published in JAMA Internal Medicine, the answer was yes. Over four monthly visits, quality of life improved and symptom burden declined at comparable rates in both groups. The hepatologists, given the right tools, matched the specialists.
Led by physicians Manisha Verma and Victor Navarro at Jefferson Einstein Philadelphia Hospital, the trial was backed by one of the largest palliative care research grants the Patient Centered Outcomes Research Institute had awarded at the time. One finding reached beyond clinical equivalence: patients reported greater satisfaction when palliative care came from their own hepatologist — a result the researchers read as evidence that continuity of relationship carries real value for people navigating serious illness.
The stakes are considerable. The United States faces a deepening shortage of palliative care specialists even as chronic illness and an aging population drive demand upward. Training enough specialists from scratch would take decades. Embedding palliative capacity within existing clinical teams — hepatologists, cardiologists, nephrologists — offers a faster path. Verma argued that the checklist-based model, not the credential itself, is what drives outcomes, making earlier and broader access genuinely achievable.
The research team is already looking beyond liver disease, with plans to extend the model to patients with advanced heart, kidney, and lung conditions, and to explore how artificial intelligence might help scale the training across health systems. What the trial has ultimately shown is that the wall between specialty palliative care and the rest of medicine is more permeable than the system has long assumed.
For patients whose livers have begun to fail, the path through the medical system is often brutal in a particular way — not just the disease itself, but the absence of anyone focused on making the suffering more bearable. Palliative care, which addresses pain, symptoms, and quality of life rather than cure, remains out of reach for many of the sickest patients in the country. A major new clinical trial suggests that gap doesn't have to stay that way.
The PAL LIVER trial, conducted across 19 medical centers in the United States, enrolled 935 patients with advanced liver disease — a condition in which severe scarring causes the organ to progressively lose function. Many of these patients had decompensated cirrhosis or liver cancer. The trial also included 559 caregivers. It is among the largest studies ever conducted in the field of liver disease palliative care.
The central question the researchers wanted to answer was deceptively simple: could a liver specialist, trained to deliver palliative care using a standardized checklist, do the job as well as a dedicated palliative care expert? The answer, published in JAMA Internal Medicine, was yes. Over four monthly visits, quality of life improved significantly in both groups. Symptom burden declined at comparable rates. Short-term mortality was similar across the board. The hepatologists, armed with the right tools and training, matched the specialists.
The trial was led by Manisha Verma and Victor Navarro, both physicians at Jefferson Einstein Philadelphia Hospital and faculty at Sidney Kimmel Medical College. Verma, who serves as associate chair and director of research for the Department of Medicine, was the study's first author. Navarro, chief clinical officer for the central region of Jefferson Health, was the senior author. Their collaboration was backed by the Patient Centered Outcomes Research Institute, which Navarro noted awarded one of its largest palliative care research grants to this project at the time of funding.
One finding stood out beyond the clinical equivalence: patients actually reported higher satisfaction when their palliative care came from their hepatologist rather than a specialist. The researchers interpret this as evidence that continuity matters — that patients with a serious, complex illness may find comfort in receiving this kind of care from the clinician who already knows their case, their history, their fears. There is something in that finding that the numbers alone don't fully capture.
The timing of the trial is not incidental. The United States faces a growing shortage of palliative care specialists, even as the population ages and the burden of serious chronic illness rises. More than 13.7 million Americans are estimated to need palliative care and lack adequate access to it. Training the specialists to meet that demand from scratch would take decades. Embedding palliative care capacity within existing clinical teams — hepatologists, cardiologists, nephrologists — offers a faster route.
Verma put it plainly: non-specialists can deliver structured palliative care effectively, provided they receive the right preparation. The model, she argued, could allow earlier and more widespread access for patients who would otherwise never receive it. The checklist-based approach used in the trial was the same for both groups, which suggests the training itself, not just the credential, is what drives outcomes.
The research team is not stopping at liver disease. Verma and Navarro have both noted that the integrated model could extend to patients with advanced heart, kidney, and lung conditions — diseases that share the same profile of serious illness, high symptom burden, and limited palliative access. They are also exploring how artificial intelligence tools might help scale the training and dissemination of the approach across health systems.
What the PAL LIVER trial has done, at its core, is demonstrate that the wall between specialty palliative care and the rest of medicine is more permeable than the system has assumed. The next question is whether health systems will act on that knowledge — and how quickly.
Notable Quotes
We've demonstrated that non-specialists can effectively deliver structured palliative care with the appropriate training.— Dr. Manisha Verma, first author and associate chair of the Department of Medicine, Jefferson Einstein Philadelphia Hospital
This patient-centered trial has the ability to significantly transform the experience for those suffering with advanced liver disease.— Dr. Victor Navarro, senior author and chief clinical officer, Jefferson Health central region
The Hearth Conversation Another angle on the story
What's the actual problem this trial is trying to solve?
There aren't enough palliative care specialists to go around, and patients with advanced liver disease are among those most likely to fall through the gap — serious illness, high symptom burden, and often no one focused on making the day-to-day bearable.
So the idea was to train liver doctors to do that job instead?
Exactly. The trial gave hepatologists a standardized checklist and training, then measured whether their patients did as well as patients seen by dedicated palliative specialists. They did.
Nine hundred and thirty-five patients across nineteen centers — that's a serious study.
It's one of the largest palliative care trials in liver disease to date. The scale matters because it makes the findings harder to dismiss as a local anomaly.
What surprised you most in the results?
The satisfaction finding. Patients weren't just equally well off — they actually preferred getting this care from their hepatologist. That's not what you'd necessarily predict.
Why do you think that is?
Continuity, probably. When you're seriously ill, the clinician who already knows your whole story may feel safer to talk to about fear and pain than a stranger, however skilled.
Does this model only work for liver disease?
The researchers don't think so. They're already pointing toward heart, kidney, and lung disease — any serious chronic condition where palliative access is limited and a specialist already has an ongoing relationship with the patient.
What's the obstacle to scaling this up?
Training, mostly. The checklist exists, but getting it into routine practice across health systems takes infrastructure. They're looking at AI tools to help with that.
And the workforce shortage — does this actually solve it?
It doesn't create more palliative specialists. But it means the shortage doesn't have to translate directly into patients going without care. That's a meaningful distinction.